hERGBoost: A gradient boosting model for quantitative IC prediction of hERG channel blockers.

Journal: Computers in biology and medicine
PMID:

Abstract

The human ether-a-go-go-related gene (hERG) potassium channel is pivotal in drug discovery due to its susceptibility to blockage by drug candidate molecules, which can cause severe cardiotoxic effects. Consequently, identifying and excluding potential hERG channel blockers at the earliest stages of drug development is crucial. Most traditional machine learning models predict a molecule's cardiotoxicity or non-cardiotoxicity typically at 10 μM, which doesn't account for compounds with low IC values that are non-toxic at therapeutic levels due to their high effectiveness at lower concentrations. To address the need for more precise, quantitative predictions, we developed hERGBoost, a cutting-edge machine learning model employing a gradient-boosting algorithm. This model demonstrates superior accuracy in predicting the IC of drug candidates. Trained on a specially curated dataset for this study, hERGBoost not only exhibited excellent performance in external validation, achieving an R score of 0.394 and a low root mean square error of 0.616 but also significantly outstripped previous models in both qualitative and quantitative assessments. Representing a notable leap forward in the prediction of hERG channel blockers, the hERGBoost model and its datasets are freely available to the drug discovery community on our web server at. http://ssbio.cau.ac.kr/software/hergboost This resource promises to be invaluable in advancing safer pharmaceutical development.

Authors

  • Myeong-Sang Yu
    School of integrative engineering, Chung-Ang University, Seoul, Republic of Korea.
  • Jingyu Lee
    School of Computer Science and Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea. Electronic address: leejingyu@cglab.snu.ac.kr.
  • Yunhyeok Lee
    Department of Biomedical Engineering, Chung-Ang University, Seoul, Republic of Korea.
  • Daeahn Cho
    Department of Biomedical Engineering, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea.
  • Kwang-Seok Oh
    Information-based Drug Research Center, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong, Daejeon, 34114, Republic of Korea.
  • Jidon Jang
    Data Convergence Drug Research Center, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, Republic of Korea.
  • Nuong Thi Nong
    Department of Biomedical Engineering, Chung-Ang University, Seoul, Republic of Korea.
  • Hyang-Mi Lee
    School of integrative engineering, Chung-Ang University, Seoul, Republic of Korea.
  • Dokyun Na
    School of integrative engineering, Chung-Ang University, Seoul, Republic of Korea. blisszen@cau.ac.kr.